XBI Quote, Financials, Valuation and Earnings

Invesco S&P SmallCap Health Care ETF has a net margin of -- compared to SPDR S&P Biotech ETF's net margin of --. SPDR S&P Biotech ETF's return on equity of -- beat Invesco S&P SmallCap Health Care ETF's return on equity of --.

SPDR S&P Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco S&P SmallCap Health Care ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Biotech ETF has higher upside potential than Invesco S&P SmallCap Health Care ETF, analysts believe SPDR S&P Biotech ETF is more attractive than Invesco S&P SmallCap Health Care ETF.

SPDR S&P Biotech ETF has a beta of 0.972, which suggesting that the stock is 2.824% less volatile than S&P 500. In comparison Invesco S&P SmallCap Health Care ETF has a beta of 0.990, suggesting its less volatile than the S&P 500 by 1.046%.

SPDR S&P Biotech ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0.15%. Invesco S&P SmallCap Health Care ETF offers a yield of 0.27% to investors and pays a quarterly dividend of $0.02 per share. SPDR S&P Biotech ETF pays -- of its earnings as a dividend. Invesco S&P SmallCap Health Care ETF pays out -- of its earnings as a dividend.

SPDR S&P Biotech ETF quarterly revenues are --, which are smaller than Invesco S&P SmallCap Health Care ETF quarterly revenues of --. SPDR S&P Biotech ETF's net income of -- is lower than Invesco S&P SmallCap Health Care ETF's net income of --. Notably, SPDR S&P Biotech ETF's price-to-earnings ratio is -- while Invesco S&P SmallCap Health Care ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Biotech ETF is -- versus -- for Invesco S&P SmallCap Health Care ETF. Usually stocks with elevated PS ratios are considered overvalued.

Invesco Dorsey Wright Healthcare Momentum ETF has a net margin of -- compared to SPDR S&P Biotech ETF's net margin of --. SPDR S&P Biotech ETF's return on equity of -- beat Invesco Dorsey Wright Healthcare Momentum ETF's return on equity of --.

SPDR S&P Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Dorsey Wright Healthcare Momentum ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Biotech ETF has higher upside potential than Invesco Dorsey Wright Healthcare Momentum ETF, analysts believe SPDR S&P Biotech ETF is more attractive than Invesco Dorsey Wright Healthcare Momentum ETF.

SPDR S&P Biotech ETF has a beta of 0.972, which suggesting that the stock is 2.824% less volatile than S&P 500. In comparison Invesco Dorsey Wright Healthcare Momentum ETF has a beta of 0.847, suggesting its less volatile than the S&P 500 by 15.315%.

SPDR S&P Biotech ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0.15%. Invesco Dorsey Wright Healthcare Momentum ETF offers a yield of 0.06% to investors and pays a quarterly dividend of $0.03 per share. SPDR S&P Biotech ETF pays -- of its earnings as a dividend. Invesco Dorsey Wright Healthcare Momentum ETF pays out -- of its earnings as a dividend.

SPDR S&P Biotech ETF quarterly revenues are --, which are smaller than Invesco Dorsey Wright Healthcare Momentum ETF quarterly revenues of --. SPDR S&P Biotech ETF's net income of -- is lower than Invesco Dorsey Wright Healthcare Momentum ETF's net income of --. Notably, SPDR S&P Biotech ETF's price-to-earnings ratio is -- while Invesco Dorsey Wright Healthcare Momentum ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Biotech ETF is -- versus -- for Invesco Dorsey Wright Healthcare Momentum ETF. Usually stocks with elevated PS ratios are considered overvalued.

ALPS Medical Breakthroughs ETF has a net margin of -- compared to SPDR S&P Biotech ETF's net margin of --. SPDR S&P Biotech ETF's return on equity of -- beat ALPS Medical Breakthroughs ETF's return on equity of --.

SPDR S&P Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand ALPS Medical Breakthroughs ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Biotech ETF has higher upside potential than ALPS Medical Breakthroughs ETF, analysts believe SPDR S&P Biotech ETF is more attractive than ALPS Medical Breakthroughs ETF.

SPDR S&P Biotech ETF has a beta of 0.972, which suggesting that the stock is 2.824% less volatile than S&P 500. In comparison ALPS Medical Breakthroughs ETF has a beta of 0.904, suggesting its less volatile than the S&P 500 by 9.65%.

SPDR S&P Biotech ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0.15%. ALPS Medical Breakthroughs ETF offers a yield of 3.52% to investors and pays a quarterly dividend of $1.17 per share. SPDR S&P Biotech ETF pays -- of its earnings as a dividend. ALPS Medical Breakthroughs ETF pays out -- of its earnings as a dividend.

SPDR S&P Biotech ETF quarterly revenues are --, which are smaller than ALPS Medical Breakthroughs ETF quarterly revenues of --. SPDR S&P Biotech ETF's net income of -- is lower than ALPS Medical Breakthroughs ETF's net income of --. Notably, SPDR S&P Biotech ETF's price-to-earnings ratio is -- while ALPS Medical Breakthroughs ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Biotech ETF is -- versus -- for ALPS Medical Breakthroughs ETF. Usually stocks with elevated PS ratios are considered overvalued.

SPDR S&P Health Care Equipment ETF has a net margin of -- compared to SPDR S&P Biotech ETF's net margin of --. SPDR S&P Biotech ETF's return on equity of -- beat SPDR S&P Health Care Equipment ETF's return on equity of --.

SPDR S&P Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Health Care Equipment ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Biotech ETF has higher upside potential than SPDR S&P Health Care Equipment ETF, analysts believe SPDR S&P Biotech ETF is more attractive than SPDR S&P Health Care Equipment ETF.

SPDR S&P Biotech ETF has a beta of 0.972, which suggesting that the stock is 2.824% less volatile than S&P 500. In comparison SPDR S&P Health Care Equipment ETF has a beta of 1.020, suggesting its more volatile than the S&P 500 by 1.999%.

SPDR S&P Biotech ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0.15%. SPDR S&P Health Care Equipment ETF offers a yield of 0.04% to investors and pays a quarterly dividend of $0.03 per share. SPDR S&P Biotech ETF pays -- of its earnings as a dividend. SPDR S&P Health Care Equipment ETF pays out -- of its earnings as a dividend.

SPDR S&P Biotech ETF quarterly revenues are --, which are smaller than SPDR S&P Health Care Equipment ETF quarterly revenues of --. SPDR S&P Biotech ETF's net income of -- is lower than SPDR S&P Health Care Equipment ETF's net income of --. Notably, SPDR S&P Biotech ETF's price-to-earnings ratio is -- while SPDR S&P Health Care Equipment ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Biotech ETF is -- versus -- for SPDR S&P Health Care Equipment ETF. Usually stocks with elevated PS ratios are considered overvalued.